Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Radiology
  • Radiology News
  • PET Imaging Can...

PET Imaging Can Predict Responders of Hormone therapy in Breast Cancer Patients

MD BureauWritten by MD Bureau Published On 2021-02-11T19:30:29+05:30  |  Updated On 12 Feb 2021 9:11 AM GMT
PET Imaging Can Predict Responders of Hormone therapy in Breast Cancer Patients

Estrogen-receptor-positivity (ER+)has significant prognostic value and is the main predictor of sensitivity to endocrine therapy (ET). However, up to 50% of ER+ breast cancers do not respond to ET. In a recent study, researchers have found that Positron Emission Tomography (PET) scan can distinguish patients likely or unlikely to benefit from hormone therapy by measuring the function of...

Estrogen-receptor-positivity (ER+)has significant prognostic value and is the main predictor of sensitivity to endocrine therapy (ET). However, up to 50% of ER+ breast cancers do not respond to ET. In a recent study, researchers have found that Positron Emission Tomography (PET) scan can distinguish patients likely or unlikely to benefit from hormone therapy by measuring the function of the estrogen receptors in their cancer cells. The study findings were published in the journal Nature Communications on February 02, 2021.

Researchers of the Washington University School of Medicine, St. Louis, USA, previously developed a progesterone receptor (PgR)-binding, progestin-analog radiopharmaceutical (21-[18F]fluorofuranylnorprogesterone [FFNP]), and demonstrated significantly greater FFNP uptake in PgR+ than PgR– breast cancers by positron emission tomography (PET) in animal models. Additionally, they have found that the increase in FFNP uptake after estrogen treatment was both rapid and robust. Therefore, they conducted a clinical study and hypothesized that a brief estradiol challenge will increase tumor progesterone receptor levels only in tumors with the functional ER.

It was a small, phase 2, prospective, single-center, single-arm trial in 43 postmenopausal women with ER+, human epidermal growth factor receptor 2-negative (HER2−) locally advanced, and locally recurrent or metastatic breast cancer. Among which 37 subjects (86%) had metastatic disease and six (14%) had either locally advanced primary cancers (n = 5) or locally recurrent disease (n = 1). Most of the patients (72%) had received prior systemic therapy. Researchers performed PET scans with FFNP to check estrogen receptor performance. Then the administered three estrogen doses over 24 hours and re-scanned participants with PET the next day.

Key findings of the study were:

• Upon evaluation, researchers found that 28 patients (65%) were responders and 15 (35%) were nonresponders.

• They noted that baseline tumor FFNP uptake did not differ significantly between responding and nonresponding patients.

• However, following estradiol challenge, they noted that tumor FFNP uptake was significantly increased compared to baseline in responding subjects but not in non-responding subjects.

• Upon hormonal therapy for six or more months, and, at follow-up, they found that the cancer was worse in the nonresponders to estrogen. While among the 28 responders, they noted 13 had remained stable, and 15 had improved.



The authors concluded, "FFNP-PET before and after administration of estradiol over 24 h can be accomplished in as little as 2 days before ET is started and discriminates likely responders from nonresponders with high accuracy, thus allowing for risk stratification equivalent to that obtained by much longer clinical observations alone. While the results of this study are extremely promising, our findings need to be confirmed in a multicenter trial before this method can be used to guide ET in clinical practice."

For further information:

https://www.nature.com/articles/s41467-020-20814-9


breast cancer oncology PET scan hormone therapy Nature Communications 
Article Source :  Â Nature Communications 
MD Bureau
MD Bureau

    Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok